Tweet
Google-translated from Arabic:
Last update 2007-12-30
New medicine ... The success of the Chinese vaccine for bird flu
China announced that it had conducted a successful second series of tests on the vaccine for the benefit of humans against avian influenza.
The news agency quoted Chinese official, deputy general manager of the company (Sainovak) Biotechnology Chinese Chang Jiang San saying that the second phase of clinical trials had been conducted as of the month of September, so in November two years and the participation of about 402 people between the ages of 18 and 60 years.
Chang added that "the results of tests showed that most indicators vaccine compatible with the international standard, where seemingly normal not have any negative reactions to the human body, this indication on the effectiveness and safety of this vaccine."
He continued, "we can control the dose and vaccination at this stage of clinical trials, which gave us the scientific and effective ways to combat severe influenza infection."
However, the reaction of the World Health Organization was cautious, as they were considered in need of further scrutiny before taking a final position on the experiment.
In the meantime, said the International Federation of Pharmaceutical Industries, in a statement reported by the media that "30 of the vaccine currently being developed in various parts of the world to find a successful drug against avian influenza."
The first series of tests took place in mid-2006.
The North Korea has claimed that it has developed for its vaccine against the virus of H5N1 bird flu deadly, and they are vaccinated poultry as part of efforts to prevent the emergence of the disease after spreading in South Korea.
It is noteworthy that the H5N1 virus has spread in an unprecedented in 2005 in the Asian countries in particular, and also extended to other countries such as Germany crashing, Egypt and Nigeria.
Last update 2007-12-30
New medicine ... The success of the Chinese vaccine for bird flu
China announced that it had conducted a successful second series of tests on the vaccine for the benefit of humans against avian influenza.
The news agency quoted Chinese official, deputy general manager of the company (Sainovak) Biotechnology Chinese Chang Jiang San saying that the second phase of clinical trials had been conducted as of the month of September, so in November two years and the participation of about 402 people between the ages of 18 and 60 years.
Chang added that "the results of tests showed that most indicators vaccine compatible with the international standard, where seemingly normal not have any negative reactions to the human body, this indication on the effectiveness and safety of this vaccine."
He continued, "we can control the dose and vaccination at this stage of clinical trials, which gave us the scientific and effective ways to combat severe influenza infection."
However, the reaction of the World Health Organization was cautious, as they were considered in need of further scrutiny before taking a final position on the experiment.
In the meantime, said the International Federation of Pharmaceutical Industries, in a statement reported by the media that "30 of the vaccine currently being developed in various parts of the world to find a successful drug against avian influenza."
The first series of tests took place in mid-2006.
The North Korea has claimed that it has developed for its vaccine against the virus of H5N1 bird flu deadly, and they are vaccinated poultry as part of efforts to prevent the emergence of the disease after spreading in South Korea.
It is noteworthy that the H5N1 virus has spread in an unprecedented in 2005 in the Asian countries in particular, and also extended to other countries such as Germany crashing, Egypt and Nigeria.
Comment